Voucher Does Not Guarantee A Priority Review, FDA Says
Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.
You may also be interested in...
House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.
US FDA program's new 2020 sunset could create a bolus of designation requests to ensure they can still get a voucher if it ends.